Format
Sort by
Items per page

Send to

Choose Destination

Best matches for Eyfjörd JE[au]:

Signatures of mutational processes in human cancer. Alexandrov LB et al. Nature. (2013)

Landscape of somatic mutations in 560 breast cancer whole-genome sequences. Nik-Zainal S et al. Nature. (2016)

HRDetect is a predictor of BRCA1 and BRCA2 deficiency based on mutational signatures. Davies H et al. Nat Med. (2017)

Search results

Items: 1 to 50 of 83

1.

Author Correction: Landscape of somatic mutations in 560 breast cancer whole-genome sequences.

Nik-Zainal S, Davies H, Staaf J, Ramakrishna M, Glodzik D, Zou X, Martincorena I, Alexandrov LB, Martin S, Wedge DC, Van Loo P, Ju YS, Smid M, Brinkman AB, Morganella S, Aure MR, Lingjærde OC, Langerød A, Ringnér M, Ahn SM, Boyault S, Brock JE, Broeks A, Butler A, Desmedt C, Dirix L, Dronov S, Fatima A, Foekens JA, Gerstung M, Hooijer GKJ, Jang SJ, Jones DR, Kim HY, King TA, Krishnamurthy S, Lee HJ, Lee JY, Li Y, McLaren S, Menzies A, Mustonen V, O'Meara S, Pauporté I, Pivot X, Purdie CA, Raine K, Ramakrishnan K, Rodríguez-González FG, Romieu G, Sieuwerts AM, Simpson PT, Shepherd R, Stebbings L, Stefansson OA, Teague J, Tommasi S, Treilleux I, Van den Eynden GG, Vermeulen P, Vincent-Salomon A, Yates L, Caldas C, Van't Veer L, Tutt A, Knappskog S, Tan BKT, Jonkers J, Borg Å, Ueno NT, Sotiriou C, Viari A, Futreal PA, Campbell PJ, Span PN, Van Laere S, Lakhani SR, Eyfjord JE, Thompson AM, Birney E, Stunnenberg HG, van de Vijver MJ, Martens JWM, Børresen-Dale AL, Richardson AL, Kong G, Thomas G, Stratton MR.

Nature. 2019 Feb;566(7742):E1. doi: 10.1038/s41586-019-0883-2.

PMID:
30659290
2.

Whole-Genome Sequencing Reveals Breast Cancers with Mismatch Repair Deficiency.

Davies H, Morganella S, Purdie CA, Jang SJ, Borgen E, Russnes H, Glodzik D, Zou X, Viari A, Richardson AL, Børresen-Dale AL, Thompson A, Eyfjord JE, Kong G, Stratton MR, Nik-Zainal S.

Cancer Res. 2017 Sep 15;77(18):4755-4762. doi: 10.1158/0008-5472.CAN-17-1083.

3.

Somatic mutations reveal asymmetric cellular dynamics in the early human embryo.

Ju YS, Martincorena I, Gerstung M, Petljak M, Alexandrov LB, Rahbari R, Wedge DC, Davies HR, Ramakrishna M, Fullam A, Martin S, Alder C, Patel N, Gamble S, O'Meara S, Giri DD, Sauer T, Pinder SE, Purdie CA, Borg Å, Stunnenberg H, van de Vijver M, Tan BK, Caldas C, Tutt A, Ueno NT, van 't Veer LJ, Martens JW, Sotiriou C, Knappskog S, Span PN, Lakhani SR, Eyfjörd JE, Børresen-Dale AL, Richardson A, Thompson AM, Viari A, Hurles ME, Nik-Zainal S, Campbell PJ, Stratton MR.

Nature. 2017 Mar 30;543(7647):714-718. doi: 10.1038/nature21703. Epub 2017 Mar 22.

4.

HRDetect is a predictor of BRCA1 and BRCA2 deficiency based on mutational signatures.

Davies H, Glodzik D, Morganella S, Yates LR, Staaf J, Zou X, Ramakrishna M, Martin S, Boyault S, Sieuwerts AM, Simpson PT, King TA, Raine K, Eyfjord JE, Kong G, Borg Å, Birney E, Stunnenberg HG, van de Vijver MJ, Børresen-Dale AL, Martens JW, Span PN, Lakhani SR, Vincent-Salomon A, Sotiriou C, Tutt A, Thompson AM, Van Laere S, Richardson AL, Viari A, Campbell PJ, Stratton MR, Nik-Zainal S.

Nat Med. 2017 Apr;23(4):517-525. doi: 10.1038/nm.4292. Epub 2017 Mar 13.

5.

Telomere Length Is Predictive of Breast Cancer Risk in BRCA2 Mutation Carriers.

Thorvaldsdottir B, Aradottir M, Stefansson OA, Bodvarsdottir SK, Eyfjörd JE.

Cancer Epidemiol Biomarkers Prev. 2017 Aug;26(8):1248-1254. doi: 10.1158/1055-9965.EPI-16-0946. Epub 2017 Feb 24.

6.

Oestrogen receptor status, treatment and breast cancer prognosis in Icelandic BRCA2 mutation carriers.

Jonasson JG, Stefansson OA, Johannsson OT, Sigurdsson H, Agnarsson BA, Olafsdottir GH, Alexiusdottir KK, Stefansdottir H, Munoz Mitev R, Olafsdottir K, Olafsdottir K, Arason A, Stefansdottir V, Olafsdottir EJ, Barkardottir RB, Eyfjord JE, Narod SA, Tryggvadóttir L.

Br J Cancer. 2016 Sep 27;115(7):776-83. doi: 10.1038/bjc.2016.249. Epub 2016 Aug 18.

7.

Corrigendum: Frequent somatic transfer of mitochondrial DNA into the nuclear genome of human cancer cells.

Ju YS, Tubio JM, Mifsud W, Fu B, Davies HR, Ramakrishna M, Li Y, Yates L, Gundem G, Tarpey PS, Behjati S, Papaemmanuil E, Martin S, Fullam A, Gerstung M; ICGC Prostate Cancer Working Group; ICGC Bone Cancer Working Group; ICGC Breast Cancer Working Group, Nangalia J, Green AR, Caldas C, Borg Å, Tutt A, Lee MT, Van't Veer LJ, Tan BK, Aparicio S, Span PN, Martens JW, Knappskog S, Vincent-Salomon A, Børresen-Dale AL, Eyfjörd JE, Myklebost O, Flanagan AM, Foster C, Neal DE, Cooper C, Eeles R, Bova GS, Lakhani SR, Desmedt C, Thomas G, Richardson AL, Purdie CA, Thompson AM, McDermott U, Yang F, Nik-Zainal S, Campbell PJ, Stratton MR.

Genome Res. 2016 May;26(5):717.2. doi: 10.1101/gr.206557.116. No abstract available.

8.

The topography of mutational processes in breast cancer genomes.

Morganella S, Alexandrov LB, Glodzik D, Zou X, Davies H, Staaf J, Sieuwerts AM, Brinkman AB, Martin S, Ramakrishna M, Butler A, Kim HY, Borg Å, Sotiriou C, Futreal PA, Campbell PJ, Span PN, Van Laere S, Lakhani SR, Eyfjord JE, Thompson AM, Stunnenberg HG, van de Vijver MJ, Martens JW, Børresen-Dale AL, Richardson AL, Kong G, Thomas G, Sale J, Rada C, Stratton MR, Birney E, Nik-Zainal S.

Nat Commun. 2016 May 2;7:11383. doi: 10.1038/ncomms11383.

9.

Landscape of somatic mutations in 560 breast cancer whole-genome sequences.

Nik-Zainal S, Davies H, Staaf J, Ramakrishna M, Glodzik D, Zou X, Martincorena I, Alexandrov LB, Martin S, Wedge DC, Van Loo P, Ju YS, Smid M, Brinkman AB, Morganella S, Aure MR, Lingjærde OC, Langerød A, Ringnér M, Ahn SM, Boyault S, Brock JE, Broeks A, Butler A, Desmedt C, Dirix L, Dronov S, Fatima A, Foekens JA, Gerstung M, Hooijer GK, Jang SJ, Jones DR, Kim HY, King TA, Krishnamurthy S, Lee HJ, Lee JY, Li Y, McLaren S, Menzies A, Mustonen V, O'Meara S, Pauporté I, Pivot X, Purdie CA, Raine K, Ramakrishnan K, Rodríguez-González FG, Romieu G, Sieuwerts AM, Simpson PT, Shepherd R, Stebbings L, Stefansson OA, Teague J, Tommasi S, Treilleux I, Van den Eynden GG, Vermeulen P, Vincent-Salomon A, Yates L, Caldas C, van't Veer L, Tutt A, Knappskog S, Tan BK, Jonkers J, Borg Å, Ueno NT, Sotiriou C, Viari A, Futreal PA, Campbell PJ, Span PN, Van Laere S, Lakhani SR, Eyfjord JE, Thompson AM, Birney E, Stunnenberg HG, van de Vijver MJ, Martens JW, Børresen-Dale AL, Richardson AL, Kong G, Thomas G, Stratton MR.

Nature. 2016 Jun 2;534(7605):47-54. doi: 10.1038/nature17676. Epub 2016 May 2. Erratum in: Nature. 2019 Feb;566(7742):E1.

10.

Inbreeding and homozygosity in breast cancer survival.

Thomsen H, Filho MI, Woltmann A, Johansson R, Eyfjörd JE, Hamann U, Manjer J, Enquist-Olsson K, Henriksson R, Herms S, Hoffmann P, Chen B, Huhn S, Hemminki K, Lenner P, Försti A.

Sci Rep. 2015 Nov 12;5:16467. doi: 10.1038/srep16467.

11.

Frequent somatic transfer of mitochondrial DNA into the nuclear genome of human cancer cells.

Ju YS, Tubio JM, Mifsud W, Fu B, Davies HR, Ramakrishna M, Li Y, Yates L, Gundem G, Tarpey PS, Behjati S, Papaemmanuil E, Martin S, Fullam A, Gerstung M; ICGC Prostate Cancer Working Group; ICGC Bone Cancer Working Group; ICGC Breast Cancer Working Group, Nangalia J, Green AR, Caldas C, Borg Å, Tutt A, Lee MT, van't Veer LJ, Tan BK, Aparicio S, Span PN, Martens JW, Knappskog S, Vincent-Salomon A, Børresen-Dale AL, Eyfjörd JE, Myklebost O, Flanagan AM, Foster C, Neal DE, Cooper C, Eeles R, Bova SG, Lakhani SR, Desmedt C, Thomas G, Richardson AL, Purdie CA, Thompson AM, McDermott U, Yang F, Nik-Zainal S, Campbell PJ, Stratton MR.

Genome Res. 2015 Jun;25(6):814-24. doi: 10.1101/gr.190470.115. Epub 2015 May 11. Erratum in: Genome Res. 2016 May;26(5):717.2.

12.

Aurora A is a prognostic marker for breast cancer arising in BRCA2 mutation carriers.

Aradottir M, Reynisdottir ST, Stefansson OA, Jonasson JG, Sverrisdottir A, Tryggvadottir L, Eyfjord JE, Bodvarsdottir SK.

J Pathol Clin Res. 2014 Nov 7;1(1):33-40. doi: 10.1002/cjp2.6. eCollection 2015 Jan.

13.

A comprehensive DNA methylation profile of epithelial-to-mesenchymal transition.

Carmona FJ, Davalos V, Vidal E, Gomez A, Heyn H, Hashimoto Y, Vizoso M, Martinez-Cardus A, Sayols S, Ferreira HJ, Sánchez-Mut JV, Morán S, Margelí M, Castella E, Berdasco M, Stefansson OA, Eyfjord JE, Gonzalez-Suarez E, Dopazo J, Orozco M, Gut IG, Esteller M.

Cancer Res. 2014 Oct 1;74(19):5608-19. doi: 10.1158/0008-5472.CAN-13-3659. Epub 2014 Aug 8.

14.

Mobile DNA in cancer. Extensive transduction of nonrepetitive DNA mediated by L1 retrotransposition in cancer genomes.

Tubio JMC, Li Y, Ju YS, Martincorena I, Cooke SL, Tojo M, Gundem G, Pipinikas CP, Zamora J, Raine K, Menzies A, Roman-Garcia P, Fullam A, Gerstung M, Shlien A, Tarpey PS, Papaemmanuil E, Knappskog S, Van Loo P, Ramakrishna M, Davies HR, Marshall J, Wedge DC, Teague JW, Butler AP, Nik-Zainal S, Alexandrov L, Behjati S, Yates LR, Bolli N, Mudie L, Hardy C, Martin S, McLaren S, O'Meara S, Anderson E, Maddison M, Gamble S, Foster C, Warren AY, Whitaker H, Brewer D, Eeles R, Cooper C, Neal D, Lynch AG, Visakorpi T, Isaacs WB, Veer LV, Caldas C, Desmedt C, Sotiriou C, Aparicio S, Foekens JA, Eyfjörd JE, Lakhani SR, Thomas G, Myklebost O, Span PN, Børresen-Dale AL, Richardson AL, Van de Vijver M, Vincent-Salomon A, Van den Eynden GG, Flanagan AM, Futreal PA, Janes SM, Bova GS, Stratton MR, McDermott U, Campbell PJ; ICGC Breast Cancer Group; ICGC Bone Cancer Group; ICGC Prostate Cancer Group.

Science. 2014 Aug 1;345(6196):1251343. doi: 10.1126/science.1251343.

15.

Systematic pathway enrichment analysis of a genome-wide association study on breast cancer survival reveals an influence of genes involved in cell adhesion and calcium signaling on the patients' clinical outcome.

Woltmann A, Chen B, Lascorz J, Johansson R, Eyfjörd JE, Hamann U, Manjer J, Enquist-Olsson K, Henriksson R, Herms S, Hoffmann P, Hemminki K, Lenner P, Försti A.

PLoS One. 2014 Jun 2;9(6):e98229. doi: 10.1371/journal.pone.0098229. eCollection 2014.

16.

Linkage of DNA methylation quantitative trait loci to human cancer risk.

Heyn H, Sayols S, Moutinho C, Vidal E, Sanchez-Mut JV, Stefansson OA, Nadal E, Moran S, Eyfjord JE, Gonzalez-Suarez E, Pujana MA, Esteller M.

Cell Rep. 2014 Apr 24;7(2):331-338. doi: 10.1016/j.celrep.2014.03.016. Epub 2014 Apr 3.

17.

Signatures of mutational processes in human cancer.

Alexandrov LB, Nik-Zainal S, Wedge DC, Aparicio SA, Behjati S, Biankin AV, Bignell GR, Bolli N, Borg A, Børresen-Dale AL, Boyault S, Burkhardt B, Butler AP, Caldas C, Davies HR, Desmedt C, Eils R, Eyfjörd JE, Foekens JA, Greaves M, Hosoda F, Hutter B, Ilicic T, Imbeaud S, Imielinski M, Jäger N, Jones DT, Jones D, Knappskog S, Kool M, Lakhani SR, López-Otín C, Martin S, Munshi NC, Nakamura H, Northcott PA, Pajic M, Papaemmanuil E, Paradiso A, Pearson JV, Puente XS, Raine K, Ramakrishna M, Richardson AL, Richter J, Rosenstiel P, Schlesner M, Schumacher TN, Span PN, Teague JW, Totoki Y, Tutt AN, Valdés-Mas R, van Buuren MM, van 't Veer L, Vincent-Salomon A, Waddell N, Yates LR; Australian Pancreatic Cancer Genome Initiative; ICGC Breast Cancer Consortium; ICGC MMML-Seq Consortium; ICGC PedBrain, Zucman-Rossi J, Futreal PA, McDermott U, Lichter P, Meyerson M, Grimmond SM, Siebert R, Campo E, Shibata T, Pfister SM, Campbell PJ, Stratton MR.

Nature. 2013 Aug 22;500(7463):415-21. doi: 10.1038/nature12477. Epub 2013 Aug 14. Erratum in: Nature. 2013 Oct 10;502(7470):258. Imielinsk, Marcin [corrected to Imielinski, Marcin].

18.

Tumour diploidy and survival in breast cancer patients with BRCA2 mutations.

Tryggvadottir L, Olafsdottir EJ, Olafsdottir GH, Sigurdsson H, Johannsson OT, Bjorgvinsson E, Alexiusdottir K, Stefansson OA, Agnarsson BA, Narod SA, Eyfjord JE, Jonasson JG.

Breast Cancer Res Treat. 2013 Jul;140(2):375-84. doi: 10.1007/s10549-013-2637-4. Epub 2013 Jul 16.

PMID:
23857704
19.

DNA methylation profiling in breast cancer discordant identical twins identifies DOK7 as novel epigenetic biomarker.

Heyn H, Carmona FJ, Gomez A, Ferreira HJ, Bell JT, Sayols S, Ward K, Stefansson OA, Moran S, Sandoval J, Eyfjord JE, Spector TD, Esteller M.

Carcinogenesis. 2013 Jan;34(1):102-8. doi: 10.1093/carcin/bgs321. Epub 2012 Oct 10.

20.

Interactive effect of genetic susceptibility with height, body mass index, and hormone replacement therapy on the risk of breast cancer.

Harlid S, Butt S, Ivarsson MI, Eyfjörd JE, Lenner P, Manjer J, Dillner J, Carlson J.

BMC Womens Health. 2012 Jun 22;12:17.

21.

Tetraploidy in BRCA2 breast tumours.

Jonsdottir AB, Stefansson OA, Bjornsson J, Jonasson JG, Ogmundsdottir HM, Eyfjord JE.

Eur J Cancer. 2012 Feb;48(3):305-10. doi: 10.1016/j.ejca.2011.11.008. Epub 2011 Nov 29.

PMID:
22133571
22.

Combined effect of low-penetrant SNPs on breast cancer risk.

Harlid S, Ivarsson MI, Butt S, Grzybowska E, Eyfjörd JE, Lenner P, Försti A, Hemminki K, Manjer J, Dillner J, Carlson J.

Br J Cancer. 2012 Jan 17;106(2):389-96. doi: 10.1038/bjc.2011.461. Epub 2011 Nov 1.

23.

Dysfunctional telomeres in human BRCA2 mutated breast tumors and cell lines.

Bodvarsdottir SK, Steinarsdottir M, Bjarnason H, Eyfjord JE.

Mutat Res. 2012 Jan 3;729(1-2):90-9. doi: 10.1016/j.mrfmmm.2011.10.002. Epub 2011 Oct 12.

PMID:
22019625
24.

Genomic and phenotypic analysis of BRCA2 mutated breast cancers reveals co-occurring changes linked to progression.

Stefansson OA, Jonasson JG, Olafsdottir K, Bjarnason H, Th Johannsson O, Bodvarsdottir SK, Valgeirsdottir S, Eyfjord JE.

Breast Cancer Res. 2011 Sep 29;13(5):R95. doi: 10.1186/bcr3020.

25.

Cytogenetic polyclonality of breast carcinomas: association with clinico-pathological characteristics and outcome.

Steinarsdottir M, Gudmundsson IH, Jonasson JG, Olafsdottir EJ, Eyfjörd JE, Ogmundsdottir HM.

Genes Chromosomes Cancer. 2011 Nov;50(11):930-9. doi: 10.1002/gcc.20915. Epub 2011 Aug 24.

PMID:
21910159
26.

Single nucleotide polymorphisms in the 20q13 amplicon genes in relation to breast cancer risk and clinical outcome.

Shi H, Bevier M, Johansson R, Grzybowska E, Chen B, Eyfjörd JE, Hamann U, Manjer J, Enquist K, Henriksson R, Carlson J, Brandt A, Lascorz J, Butkiewicz D, Pamula-Pilat J, Tecza K, Herms S, Hoffmann P, Hemminki K, Lenner P, Försti A.

Breast Cancer Res Treat. 2011 Dec;130(3):905-16. doi: 10.1007/s10549-011-1600-5. Epub 2011 Jun 1.

PMID:
21630024
27.

CpG island hypermethylation of BRCA1 and loss of pRb as co-occurring events in basal/triple-negative breast cancer.

Stefansson OA, Jonasson JG, Olafsdottir K, Hilmarsdottir H, Olafsdottir G, Esteller M, Johannsson OT, Eyfjord JE.

Epigenetics. 2011 May;6(5):638-49. doi: 10.4161/epi.6.5.15667.

28.

A candidate CpG SNP approach identifies a breast cancer associated ESR1-SNP.

Harlid S, Ivarsson MI, Butt S, Hussain S, Grzybowska E, Eyfjörd JE, Lenner P, Försti A, Hemminki K, Manjer J, Dillner J, Carlson J.

Int J Cancer. 2011 Oct 1;129(7):1689-98. doi: 10.1002/ijc.25786. Epub 2011 Mar 11.

29.

Germline Brca2 heterozygosity promotes Kras(G12D) -driven carcinogenesis in a murine model of familial pancreatic cancer.

Skoulidis F, Cassidy LD, Pisupati V, Jonasson JG, Bjarnason H, Eyfjord JE, Karreth FA, Lim M, Barber LM, Clatworthy SA, Davies SE, Olive KP, Tuveson DA, Venkitaraman AR.

Cancer Cell. 2010 Nov 16;18(5):499-509. doi: 10.1016/j.ccr.2010.10.015. Epub 2010 Nov 4.

30.

Sensitivity of BRCA2 mutated human cell lines to Aurora kinase inhibition.

Vidarsdottir L, Steingrimsdottir G, Bodvarsdottir SK, Ogmundsdottir HM, Eyfjord JE.

Invest New Drugs. 2012 Apr;30(2):425-34. doi: 10.1007/s10637-010-9566-4. Epub 2010 Oct 20.

PMID:
20960027
31.

Centriole movements in mammalian epithelial cells during cytokinesis.

Jonsdottir AB, Dirks RW, Vrolijk J, Ogmundsdottir HM, Tanke HJ, Eyfjörd JE, Szuhai K.

BMC Cell Biol. 2010 May 21;11:34. doi: 10.1186/1471-2121-11-34.

32.

Genomic profiling of breast tumours in relation to BRCA abnormalities and phenotypes.

Stefansson OA, Jonasson JG, Johannsson OT, Olafsdottir K, Steinarsdottir M, Valgeirsdottir S, Eyfjord JE.

Breast Cancer Res. 2009;11(4):R47. doi: 10.1186/bcr2334. Epub 2009 Jul 9. Erratum in: Breast Cancer Res. 2009;11(5):404.

33.

BRCA2 heterozygosity delays cytokinesis in primary human fibroblasts.

Jonsdottir AB, Vreeswijk MP, Wolterbeek R, Devilee P, Tanke HJ, Eyfjörd JE, Szuhai K.

Cell Oncol. 2009;31(3):191-201. doi: 10.3233/CLO-2009-0465.

34.

The BOADICEA model of genetic susceptibility to breast and ovarian cancers: updates and extensions.

Antoniou AC, Cunningham AP, Peto J, Evans DG, Lalloo F, Narod SA, Risch HA, Eyfjord JE, Hopper JL, Southey MC, Olsson H, Johannsson O, Borg A, Pasini B, Radice P, Manoukian S, Eccles DM, Tang N, Olah E, Anton-Culver H, Warner E, Lubinski J, Gronwald J, Gorski B, Tryggvadottir L, Syrjakoski K, Kallioniemi OP, Eerola H, Nevanlinna H, Pharoah PD, Easton DF.

Br J Cancer. 2008 Apr 22;98(8):1457-66. doi: 10.1038/sj.bjc.6604305. Epub 2008 Mar 18. Erratum in: Br J Cancer. 2008 Jun 17;98(12):2015. Passini, B [corrected to Pasini, B].

35.

AURKA and breast cancer in BRCA1/2 mutation carriers.

Bodvarsdottir SK, Vidarsdottir L, Eyfjord JE.

Cancer Epidemiol Biomarkers Prev. 2007 Nov;16(11):2517. No abstract available.

36.

Positive association between DNA strand breaks in peripheral blood mononuclear cells and polyunsaturated fatty acids in red blood cells from women.

Thorlaksdottir AY, Jonsson JJ, Tryggvadottir L, Skuladottir GV, Petursdottir AL, Ogmundsdottir HM, Eyfjord JE, Hardardottir I.

Nutr Cancer. 2007;59(1):21-8.

PMID:
17927498
37.

Positive association between plasma antioxidant capacity and n-3 PUFA in red blood cells from women.

Thorlaksdottir AY, Skuladottir GV, Petursdottir AL, Tryggvadottir L, Ogmundsdottir HM, Eyfjord JE, Jonsson JJ, Hardardottir I.

Lipids. 2006 Feb;41(2):119-25.

PMID:
17707977
38.

MYC amplification and TERT expression in breast tumor progression.

Bodvarsdóttir SK, Steinarsdóttir M, Hilmarsdóttir H, Jónasson JG, Eyfjörd JE.

Cancer Genet Cytogenet. 2007 Jul 15;176(2):93-9.

PMID:
17656250
39.

Prostate cancer progression and survival in BRCA2 mutation carriers.

Tryggvadóttir L, Vidarsdóttir L, Thorgeirsson T, Jonasson JG, Olafsdóttir EJ, Olafsdóttir GH, Rafnar T, Thorlacius S, Jonsson E, Eyfjord JE, Tulinius H.

J Natl Cancer Inst. 2007 Jun 20;99(12):929-35. Epub 2007 Jun 12.

PMID:
17565157
40.

Breast cancer risk associated with AURKA 91T -->A polymorphism in relation to BRCA mutations.

Vidarsdottir L, Bodvarsdottir SK, Hilmarsdottir H, Tryggvadottir L, Eyfjord JE.

Cancer Lett. 2007 Jun 8;250(2):206-12. Epub 2006 Nov 17.

PMID:
17113223
41.

Aurora-A amplification associated with BRCA2 mutation in breast tumours.

Bodvarsdottir SK, Hilmarsdottir H, Birgisdottir V, Steinarsdottir M, Jonasson JG, Eyfjord JE.

Cancer Lett. 2007 Apr 8;248(1):96-102. Epub 2006 Jul 24.

PMID:
16860930
42.

Epigenetic silencing and deletion of the BRCA1 gene in sporadic breast cancer.

Birgisdottir V, Stefansson OA, Bodvarsdottir SK, Hilmarsdottir H, Jonasson JG, Eyfjord JE.

Breast Cancer Res. 2006;8(4):R38.

43.

Population-based study of changing breast cancer risk in Icelandic BRCA2 mutation carriers, 1920-2000.

Tryggvadottir L, Sigvaldason H, Olafsdottir GH, Jonasson JG, Jonsson T, Tulinius H, Eyfjörd JE.

J Natl Cancer Inst. 2006 Jan 18;98(2):116-22.

PMID:
16418514
44.

Genomic instability and cancer: networks involved in response to DNA damage.

Eyfjord JE, Bodvarsdottir SK.

Mutat Res. 2005 Dec 30;592(1-2):18-28. Epub 2005 Jul 5. Review.

PMID:
16002101
45.

Breast and ovarian cancer risks to carriers of the BRCA1 5382insC and 185delAG and BRCA2 6174delT mutations: a combined analysis of 22 population based studies.

Antoniou AC, Pharoah PD, Narod S, Risch HA, Eyfjord JE, Hopper JL, Olsson H, Johannsson O, Borg A, Pasini B, Radice P, Manoukian S, Eccles DM, Tang N, Olah E, Anton-Culver H, Warner E, Lubinski J, Gronwald J, Gorski B, Tulinius H, Thorlacius S, Eerola H, Nevanlinna H, Syrjäkoski K, Kallioniemi OP, Thompson D, Evans C, Peto J, Lalloo F, Evans DG, Easton DF.

J Med Genet. 2005 Jul;42(7):602-3.

46.

The Icelandic founder mutation BRCA2 999del5: analysis of expression.

Mikaelsdottir EK, Valgeirsdottir S, Eyfjord JE, Rafnar T.

Breast Cancer Res. 2004;6(4):R284-90. Epub 2004 Apr 7.

47.

BRCA2 mutation carriers, reproductive factors and breast cancer risk.

Tryggvadottir L, Olafsdottir EJ, Gudlaugsdottir S, Thorlacius S, Jonasson JG, Tulinius H, Eyfjord JE.

Breast Cancer Res. 2003;5(5):R121-8. Epub 2003 Jun 24.

48.

Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case Series unselected for family history: a combined analysis of 22 studies.

Antoniou A, Pharoah PD, Narod S, Risch HA, Eyfjord JE, Hopper JL, Loman N, Olsson H, Johannsson O, Borg A, Pasini B, Radice P, Manoukian S, Eccles DM, Tang N, Olah E, Anton-Culver H, Warner E, Lubinski J, Gronwald J, Gorski B, Tulinius H, Thorlacius S, Eerola H, Nevanlinna H, Syrjäkoski K, Kallioniemi OP, Thompson D, Evans C, Peto J, Lalloo F, Evans DG, Easton DF.

Am J Hum Genet. 2003 May;72(5):1117-30. Epub 2003 Apr 3. Erratum in: Am J Hum Genet. 2003 Sep;73(3):709.

49.

CYP17 promoter polymorphism and breast cancer risk in males and females in relation to BRCA2 status.

Gudmundsdottir K, Thorlacius S, Jonasson JG, Sigfusson BF, Tryggvadottir L, Eyfjord JE.

Br J Cancer. 2003 Mar 24;88(6):933-6.

50.

DLC-1 gene inhibits human breast cancer cell growth and in vivo tumorigenicity.

Yuan BZ, Zhou X, Durkin ME, Zimonjic DB, Gumundsdottir K, Eyfjord JE, Thorgeirsson SS, Popescu NC.

Oncogene. 2003 Jan 23;22(3):445-50.

PMID:
12545165

Supplemental Content

Loading ...
Support Center